BLMS.US Bloomios Inc
- Market cap
- USD 19.3K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is BLMS.US undervalued?
Graham numberThe Graham number of Bloomios Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bloomios Inc fundamental analysis
No fundamental analysis for Bloomios Inc yet.
Bloomios Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bloomios Inc
Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company's product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to Bloomios, Inc. in April 2021. Bloomios, Inc. was incorporated in 2001 and is he…
Full company profileBloomios Inc financial statements
Bloomios Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2003 | 2004 | 2005 | 2006 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 1.32M | 8.49M | 6.08M | 8.23M |
| Gross Profit | -1.98K | - | - | - | - | 0.00 | 402K | 3.78M | 2.23M | 2.05M |
| Operating Income | -63.2K | -806K | -180K | -99.6K | -10.0K | -466K | -16.9K | -800K | -4.14M | -5.02M |
| EBITDA | -63.2K | 480K | 738K | -99.6K | -10.0K | -490K | 179K | -1.38M | -12.4M | - |
| Net Income | -63.2K | -2.25M | 681K | -108K | -10.0K | -490K | -16.9K | -2.01M | -13.8M | -39.6M |
| EPS | -0.04 | -4.32 | 1.31 | -0.21 | 0.00 | -0.04 | 0.00 | -0.16 | -1.04 | - |
| Balance Sheet | ||||||||||
| Total Assets | 6.17K | 24.9K | 5.28K | 10.4K | 0.00 | 1.05K | 3.19M | 4.01M | 26.0M | - |
| Total Liabilities | 9.04K | 1.47M | 630K | 750K | 0.00 | 474K | 4.46M | 5.58M | 27.3M | - |
| Shareholders' Equity | -2.88K | -1.45M | -625K | -739K | 0.00 | -473K | -1.26M | -1.57M | -1.32M | - |
| Cash & Short-term Investments | 6.17K | 24.9K | 5.28K | 10.4K | 0.00 | 1.05K | 122K | 271K | 118K | - |
| Total Debt | - | 876K | 366K | 397K | - | - | 1.87M | 2.56M | 22.5M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -50.2K | -563K | -89.6K | -23.4K | -10.0K | -16.9K | 821K | -98.5K | -6.33M | -7.11M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 2.30M | 2.30M | 2.30M | 798K | 24.2K | 0.00 |
| Free Cash Flow | -50.2K | -563K | -89.6K | -23.4K | -10.0K | -57.1K | -1.48M | -897K | -6.35M | -7.11M |
| Ratios | ||||||||||
| ROA | -1,025.4% | -9,011.8% | 12,895.3% | -1,035.7% | - | -46,912.3% | -0.5% | -50.2% | -53.0% | - |
| Net Profit Margin | - | - | - | - | - | - | -1.3% | -23.7% | -226.7% | -481.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bloomios Inc dividends
Bloomios Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:50 on Dec 11, 2006.
Who owns Bloomios Inc
- Insiders 36.31%
- Institutions 0.00%
- Public & others 63.69%
- Shares outstanding 64.5M
- Free float 42.2M
Bloomios Inc company profile
- Company name
- Bloomios Inc
- Ticker
- BLMS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 701 Anacapa Street, Santa Barbara, CA, United States, 93101
- Phone
- 805 222 6330
- Website
- bloomios.com
About Bloomios Inc
Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company's product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to Bloomios, Inc. in April 2021. Bloomios, Inc. was incorporated in 2001 and is headquartered in Santa Barbara, California.
Bloomios Inc management
2- Mr. Michael HillCEO & Chairman · born 1976
- Mr. Barrett EvansChief Strategy Officer, President, Secretary & Director · born 1973